GDS Wealth Management Has $7.28 Million Position in Boston Scientific Corporation $BSX

Key Points

• GDS Wealth Management increased its holdings in Boston Scientific Corporation by 234% during the first quarter, owning a total of 72,121 shares valued at approximately $7.3 million.
• Insiders have sold a total of 345,029 shares of Boston Scientific in the last three months, with significant sales by Director Yoshiaki Fujimori and EVP Joseph Michael Fitzgerald.
• Boston Scientific has received a consensus rating of "Buy" from analysts, with an average price target of $117.50, following strong quarterly earnings that exceeded expectations.

GDS Wealth Management increased its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 234.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 72,121 shares of the medical equipment provider's stock after purchasing an additional 50,525 shares during the quarter. GDS Wealth Management's holdings in Boston Scientific were worth $7,276,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in shares of Boston Scientific by 11,720.3% in the first quarter. GAMMA Investing LLC now owns 2,577,887 shares of the medical equipment provider's stock worth $260,057,000 after acquiring an additional 2,556,078 shares in the last quarter. Northern Trust Corp boosted its stake in Boston Scientific by 18.0% during the 4th quarter. Northern Trust Corp now owns 14,595,627 shares of the medical equipment provider's stock valued at $1,303,681,000 after acquiring an additional 2,221,790 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Boston Scientific by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock valued at $968,172,000 after acquiring an additional 1,709,461 shares during the last quarter. Vanguard Group Inc. grew its holdings in Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after acquiring an additional 1,697,945 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of Boston Scientific by 161.9% during the first quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider's stock worth $250,757,000 after purchasing an additional 1,536,663 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the sale, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. The trade was a 42.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the sale, the executive vice president owned 178,342 shares of the company's stock, valued at approximately $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 345,029 shares of company stock valued at $35,976,603. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Price Performance

NYSE:BSX traded down $0.0990 during midday trading on Monday, hitting $106.0710. 1,461,192 shares of the stock were exchanged, compared to its average volume of 7,529,732. The company has a market capitalization of $157.17 billion, a price-to-earnings ratio of 63.11, a P/E/G ratio of 2.56 and a beta of 0.66. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a one year low of $78.90 and a one year high of $108.94. The business has a 50-day moving average price of $104.10 and a two-hundred day moving average price of $102.12.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The company's quarterly revenue was up 22.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Morgan Stanley lifted their target price on Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, May 16th. UBS Group raised their price target on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Jefferies Financial Group reaffirmed a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Barclays lifted their target price on Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Finally, Raymond James Financial upped their target price on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a report on Thursday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and a consensus price target of $117.50.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.